4.6 Review

SOCS1 and SOCS3 in the control of CNS immunity

Journal

TRENDS IN IMMUNOLOGY
Volume 30, Issue 8, Pages 392-400

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.it.2009.07.001

Keywords

-

Categories

Funding

  1. National Institutes of Health [NS-57563, NS-50665]
  2. National Multiple Sclerosis Society [RG 3892-A-12]
  3. NIH [T32-NS-48039, T32-AI-07493, F30-NS-65600]

Ask authors/readers for more resources

In the decade following their initial discovery, the suppressor of cytokine signaling (SOCS) proteins have been studied for their potential use as immunomodulators in disease. SOCS proteins, especially SOCS1 and SOCS3, are expressed by immune cells and cells of the central nervous system (CNS) and have the potential to impact immune processes within the CNS, including inflammatory cytokine and chemokine production, activation of microglia, macrophages and astrocytes, immune cell infiltration and autoimmunity. We describe CNS-relevant in vitro and in vivo studies that have examined the function of SOCS1 or SOCS3 under various neuroinflammatory or neuropathological conditions, including exposure of CNS cells to inflammatory cytokines or bacterial infection, demyelinating insults, stroke, spinal cord injury, multiple sclerosis and glioblastoma multiforme.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available